Swiss National Bank Grows Stock Holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

Swiss National Bank increased its stake in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 34.4% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 426,600 shares of the biopharmaceutical company’s stock after buying an additional 109,100 shares during the quarter. Swiss National Bank’s holdings in Lexicon Pharmaceuticals were worth $315,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. FMR LLC boosted its holdings in Lexicon Pharmaceuticals by 28.9% in the third quarter. FMR LLC now owns 49,867,042 shares of the biopharmaceutical company’s stock worth $78,291,000 after acquiring an additional 11,179,919 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Lexicon Pharmaceuticals by 8.4% in the 3rd quarter. Geode Capital Management LLC now owns 3,523,971 shares of the biopharmaceutical company’s stock worth $5,534,000 after purchasing an additional 273,436 shares during the last quarter. State Street Corp boosted its stake in Lexicon Pharmaceuticals by 6.8% in the 3rd quarter. State Street Corp now owns 2,471,215 shares of the biopharmaceutical company’s stock worth $3,880,000 after purchasing an additional 157,738 shares in the last quarter. Barclays PLC grew its position in Lexicon Pharmaceuticals by 391.6% during the 3rd quarter. Barclays PLC now owns 193,873 shares of the biopharmaceutical company’s stock valued at $304,000 after purchasing an additional 154,436 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. increased its stake in Lexicon Pharmaceuticals by 18.1% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 863,255 shares of the biopharmaceutical company’s stock valued at $638,000 after purchasing an additional 132,117 shares in the last quarter. Hedge funds and other institutional investors own 74.70% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on LXRX. Needham & Company LLC reiterated a “hold” rating on shares of Lexicon Pharmaceuticals in a research note on Monday, March 3rd. StockNews.com initiated coverage on Lexicon Pharmaceuticals in a research report on Friday. They issued a “sell” rating on the stock. HC Wainwright restated a “buy” rating and issued a $4.00 price target on shares of Lexicon Pharmaceuticals in a research note on Friday. Piper Sandler lowered their price target on Lexicon Pharmaceuticals from $10.00 to $6.00 and set an “overweight” rating on the stock in a report on Friday, March 7th. Finally, Leerink Partners reiterated a “market perform” rating and issued a $1.00 price objective (down from $2.00) on shares of Lexicon Pharmaceuticals in a report on Tuesday, March 4th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, Lexicon Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $3.67.

Lexicon Pharmaceuticals Trading Up 64.1 %

NASDAQ:LXRX opened at $0.57 on Monday. The company has a market cap of $140.48 million, a PE ratio of -0.76 and a beta of 1.04. The company has a current ratio of 7.45, a quick ratio of 7.43 and a debt-to-equity ratio of 0.56. The company has a 50 day simple moving average of $0.61 and a two-hundred day simple moving average of $0.99. Lexicon Pharmaceuticals, Inc. has a 12 month low of $0.28 and a 12 month high of $2.45.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings data on Thursday, March 6th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.02. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. The company had revenue of $26.55 million during the quarter, compared to analyst estimates of $6.48 million. Research analysts forecast that Lexicon Pharmaceuticals, Inc. will post -0.66 earnings per share for the current year.

Lexicon Pharmaceuticals Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.